These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21245091)

  • 1. An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma.
    Asundi J; Reed C; Arca J; McCutcheon K; Ferrando R; Clark S; Luis E; Tien J; Firestein R; Polakis P
    Clin Cancer Res; 2011 Mar; 17(5):965-75. PubMed ID: 21245091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
    Tse KF; Jeffers M; Pollack VA; McCabe DA; Shadish ML; Khramtsov NV; Hackett CS; Shenoy SG; Kuang B; Boldog FL; MacDougall JR; Rastelli L; Herrmann J; Gallo M; Gazit-Bornstein G; Senter PD; Meyer DL; Lichenstein HS; LaRochelle WJ
    Clin Cancer Res; 2006 Feb; 12(4):1373-82. PubMed ID: 16489096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.
    Zhou LT; Liu FY; Li Y; Peng YM; Liu YH; Li J
    Neoplasma; 2012; 59(1):1-5. PubMed ID: 22017590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
    Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
    Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.
    Jackson D; Gooya J; Mao S; Kinneer K; Xu L; Camara M; Fazenbaker C; Fleming R; Swamynathan S; Meyer D; Senter PD; Gao C; Wu H; Kinch M; Coats S; Kiener PA; Tice DA
    Cancer Res; 2008 Nov; 68(22):9367-74. PubMed ID: 19010911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
    Lo AS; Ma Q; Liu DL; Junghans RP
    Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis.
    Saleem M; Maddodi N; Abu Zaid M; Khan N; bin Hafeez B; Asim M; Suh Y; Yun JM; Setaluri V; Mukhtar H
    Clin Cancer Res; 2008 Apr; 14(7):2119-27. PubMed ID: 18381953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models.
    Chen Q; Millar HJ; McCabe FL; Manning CD; Steeves R; Lai K; Kellogg B; Lutz RJ; Trikha M; Nakada MT; Anderson GM
    Clin Cancer Res; 2007 Jun; 13(12):3689-95. PubMed ID: 17575234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NDRG2 gene expression in B16F10 melanoma cells restrains melanogenesis via inhibition of Mitf expression.
    Kim A; Yang Y; Lee MS; Yoo YD; Lee HG; Lim JS
    Pigment Cell Melanoma Res; 2008 Dec; 21(6):653-64. PubMed ID: 19067970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
    Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
    Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
    Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ
    Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
    Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
    Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survivin knockdown by short hairpin RNA abrogates the growth of human hepatocellular carcinoma xenografts in nude mice.
    Zhang R; Ma L; Zheng M; Ren J; Wang T; Meng Y; Zhao J; Jia L; Yao L; Han H; Li K; Yang A
    Cancer Gene Ther; 2010 Apr; 17(4):275-88. PubMed ID: 19876077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poorly metastatic tumor cell variants as primary targets of syngeneic antibody responses against murine melanoma.
    Parratto NP; Odebralski JM; Kimura AK
    Cancer Res; 1989 Jul; 49(14):3722-8. PubMed ID: 2736512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates.
    Dillman RO; Johnson DE; Ogden J; Beidler D
    Mol Biother; 1989; 1(5):250-5. PubMed ID: 2515870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.